Atara Biotherapeutics, Inc.ATRANASDAQ
Loading
Operating Income Growth AcceleratingAccelerating
Percentile Rank85
3Y CAGR+36.0%
Year-over-Year Change
Year-over-year operating income growth rate
3Y CAGR
+36.0%/yr
vs +36.1%/yr prior
Acceleration
-0.1pp
Decelerating
Percentile
P85
Within normal range
vs 3Y Ago
2.5x
Strong expansion
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 26.98% |
| Q3 2025 | -210.95% |
| Q2 2025 | -91.76% |
| Q1 2025 | 417.97% |
| Q4 2024 | 43.91% |
| Q3 2024 | -19.34% |
| Q2 2024 | 41.66% |
| Q1 2024 | 41.35% |
| Q4 2023 | 23.47% |
| Q3 2023 | 2.52% |
| Q2 2023 | 4.80% |
| Q1 2023 | 0.69% |
| Q4 2022 | 10.73% |
| Q3 2022 | -163.36% |
| Q2 2022 | 63.58% |
| Q1 2022 | 5.55% |
| Q4 2021 | -10.13% |
| Q3 2021 | -0.96% |
| Q2 2021 | -7.36% |
| Q1 2021 | 4.23% |
| Q4 2020 | -9.36% |
| Q3 2020 | 4.16% |
| Q2 2020 | -4.36% |
| Q1 2020 | 6.28% |
| Q4 2019 | -9.84% |
| Q3 2019 | 3.94% |
| Q2 2019 | -11.26% |
| Q1 2019 | 17.02% |
| Q4 2018 | -35.86% |
| Q3 2018 | -14.44% |
| Q2 2018 | -23.96% |
| Q1 2018 | -18.57% |
| Q4 2017 | -13.08% |
| Q3 2017 | -13.44% |
| Q2 2017 | -6.68% |
| Q1 2017 | -39.50% |
| Q4 2016 | 27.71% |
| Q3 2016 | -33.14% |
| Q2 2016 | -14.21% |
| Q1 2016 | 21.63% |